Sheiner LB. 1997. ‘Learning versus confirming in
clinical drug development’.Clin. Pharmacol. Ther.
61 : 275–291.
Urquhart J. 1991. ‘Patient compliance as an explanatory
variable in four selected cardiovascular studies’. In
Compliance in Medical Practice and Clinical Trials,
Cramer JA, Spilker B (eds). New York: Raven Press;
301–322.
Urquhart J. 1993. ‘Ascertaining how much compliance
is enough with outpatient antibiotic regimens’.Post-
grad. Med. J. 68 (Suppl. 3): 49–59.
Urquhart J. 1997. ‘The electronic medication event
monitor – lessons for pharmacotherapy’.Clin. Phar-
macokinet. 32 : 345–356.
Urquhart J. 1998. ‘Pharmacodynamics of variable
patient compliance: implications for pharmaceutical
value’.Adv. Drug Deliv. Rev. 33 : 207–219.
Urquhart J. 1999. ‘Pharmacoeconomic consequences of
variable patient compliance with prescribed drug
regimens’.Pharmacoeconomics 15 : 217–28.
Urquhart J. 2000. ‘Defining the margins for errors in
patient compliance with prescribed drug regimens’.
Pharmacoeepidemiol. Drug Safety 9 : 565–568.
Urquhart J. 2001. ‘Some economic consequences of
noncompliance’.Curr. Hypertens. Rep. 3 : 473–480.
Urquhart J. 2002. ‘History-informed perspectives on the
modeling and simulation of therapeutic drug
actions’. InSimulation for Designing Clinical Trials,
Kimko HC, Duffull S (eds). New York: Marcel-
Dekker; 245–269.
Urquhart J, Chevalley C. 1988. ‘Impact of unrecognized
dosing errors on the cost and effectiveness of phar-
maceuticals’.Drug Inf. J. 22 : 363–378.
Urquhart J, de Klerk E. 1998. ‘Contending paradigms for
the interpretation of data on patient compliance with
therapeutic drug regimens’.Stat Med 17 : 251–267.
Vanhove GF, Schapiro JM, Winters MA, Merigan TC,
Blaschke TF. 1996. ‘Patient compliance and drug
failure in protease inhibitor monotherapy’.JAMA
276 : 1955–1956.
Vrijens B. 2002.Analyzing Time-Varying Patterns of
Human Exposure to Xenobiotics and Their Biome-
dical Impact.PhD thesis. Belgium: University of
Gent.
Vrijens B, Mayer SL, Rode R, Bertz R, Urquhart
J. 2003. ‘Dose-timing information improves the
clinical explanatory power of data on patient adher-
ence to antiretroviral drug regimens’. InProceedings
of the 12th PAGE Meeting, Verona, Italy, 12–13
June.
Vrijens B, Ringe JD, Watts NB, Pols HAP, Roux C,
Eastell R,et al. 2003. ‘Electronic monitoring of
adherence to therapy in postmenopausal osteoporo-
sis: the impact study’. InEuropean Calcified Tissues
Society Meeting, Rome, 8–12 May.
Vrijens B, Tousset E, Rode R, Bertz R, Mayer SL. 2003.
‘Within-patient variance reduced in an ARV PK
study by switching from patient-reported to electro-
nically-compiled dosing times’. InProceedings of
the 2nd IAS Conference on HIV Pathogenesis and
Treatment, Paris, France, 13–16 July.
Wagner GJ. 2002. ‘Predictors of antiretroviral adher-
ence as measured by self-report, electronic monitor-
ing, and medication diaries’. AIDS Patient Care
STDS 16 : 599–608.
Waterhouse DM, Calzone KA, Mele C, Brenner DE.- ‘Adherence to oral tamoxifen: a comparison of
patient self-report, pill counts, and microelectronic
monitoring’.J. Clin. Oncol. 11 : 1189–1197.
World Health Organization. 2004.Adherence to Long-
term Therapies. Geneva: World Health Organiza-
tion.
REFERENCES 373